Treatment With AX200 for Acute Ischemic Stroke


Phase 2 Results


There were no significant differences in the number of thromboembolic complications through discharge/day 4, with 3 out of 14 (21%) occurring in the placebo group and 3 out of 30 (10%) for the treatment group. No detectable differences between the placebo and treatment groups for efficacy. No fatal outcomes after 2 weeks of treatment. 1 fatality in the placebo group and 3 in the treatment group after 90 days of treatment, but not of neurological cause or related to medication. There were no severe infections or anaphylactic reactions to medication, no clinically relevant decrease in thrombocyte count or increase in hematocrit, and no significant differences in asymptomatic hemorrhages. There were no symptomatic hemorrhages in either group, and no signficant differences in symptomatic ICHs through 3 months.